Projects per year
Abstract
Leucine-rich repeat kinase 2 (LRRK2) is linked to Parkinson's disease and may represent an attractive therapeutic target. Here we report a 2,4-dianilino-5-chloro-pyrimidine, TAE684, a previously reported inhibitor of anaplastic lymphoma kinase (ALK), is also a potent inhibitor of LRRK2 kinase activity (IC50 of 7.8 nM against wild-type LRRK2, 6.1 nM against the G2019S mutant). TAE684 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3 mu M in cells and in mouse spleen and kidney, but not in brain, following oral doses of 10 mg/kg. (c) 2012 Elsevier Ltd. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 1864-1869 |
Number of pages | 6 |
Journal | Bioorganic & Medicinal Chemistry Letters |
Volume | 22 |
Issue number | 5 |
Early online date | 28 Jan 2012 |
DOIs | |
Publication status | Published - 1 Mar 2012 |
Keywords
- Animals
- Brain
- Cell Line
- Cells, Cultured
- Humans
- Mice
- Models, Molecular
- Mutation
- Parkinson Disease
- Protein-Serine-Threonine Kinases
- Pyrimidines